Back to Search
ARLENE SIEFKER-RADTKE, M.D.
M.D.
Medical Oncology Physician
NPI: 1700979275IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
L2652(TX)
Education
JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
Class of 1996
Research & Publications (19)
Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer.
PMID 19414678·J Clin Oncol·2009
3-trial
Urachal carcinoma: surgical and chemotherapeutic options.
PMID 17181485·Expert Rev Anticancer Ther·2006
6-review
Systemic chemotherapy options for metastatic bladder cancer.
PMID 16761931·Expert Rev Anticancer Ther·2006
6-review
Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience.
PMID 15247709·J Urol·2004
8-other
Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience.
PMID 14665863·J Urol·2004
8-other
Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience.
PMID 12629346·J Urol·2003
8-other
Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer.
PMID 11870180·J Clin Oncol·2002
3-trial
miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy.
PMID 19671845·Clin Cancer Res·2009
4-observational
Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy.
PMID 18848348·Urology·2009
8-other
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
PMID 18635226·J Urol·2008
3-trial
Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells.
PMID 18316572·Clin Cancer Res·2008
7-preclinical
Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience.
PMID 17614317·Cancer·2007
8-other
Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients.
PMID 17542024·Cancer·2007
8-other
P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors.
PMID 17434254·Eur Urol·2007
8-other
Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma.
PMID 17029276·Cancer·2006
3-trial
Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma.
PMID 16795067·Cancer·2006
3-trial
Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience.
PMID 16697803·J Urol·2006
8-other
Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases.
PMID 15656887·Histopathology·2005
5-case
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1515 HOLCOMBE BLVD, 77030-4009
HOUSTON, TX 77030 - Phone
- (713) 792-6161
Quick Facts
- NPI
- 1700979275
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 30
- Publications
- 19
Are you this provider?
Claim Your Profile